Victoria Robinson

We break down the drivers of the Affordable Care Act premium increases and explore implications for future plan years.

With the expansion of the Medicare Drug Price Negotiation Program to include Part B drugs for 2028, stakeholders need to understand the expected impacts.

We outline the role of six major stakeholders in the pharmacy supply chain to give life sciences companies a better understanding of the system.

We look at how group Medicare Advantage compares to alternative group retiree healthcare options.